In Psychiatric Times: Frontiers in Synaptic Regeneration: Tazbentetol as a Potential Treatment for Schizophrenia

Schizophrenia treatment has traditionally focused on symptom management, primarily through drugs targeting dopamine receptors and, more recently the cholinergic system, which help reduce the “positive symptoms” of the disease. However, most patients remain inadequately controlled on existing therapies, especially with respect to the negative and cognitive symptoms of the disease, with little to no impact…

In The Scientist: Regenerating Synapses Could Help Treat Neurodegenerative Diseases

By Dr. Peter Vanderklish Many neurological disorders appear very different clinically, yet an important biological theme is emerging across them: early loss of synaptic connectivity. In a recent article published in The Scientist, Dr. Vanderklish, Chief Science Officer at Spinogenix, examines synapse loss as a point of convergence across conditions including Alzheimer’s disease, amyotrophic lateral…

Spinogenix CEO and Founder Named to Forbes 50 Over 50: Innovation List

We’re thrilled to share that our CEO and Founder, Stella Sarraf, PhD, has been named to Forbes 2025 Class of 50 Over 50: Innovation list. This recognition celebrates trailblazers who are redefining what’s possible in science, technology, and business—and we couldn’t be prouder to see Stella honored for her bold vision and unwavering commitment to…

Addressing the unmet need for synaptic regeneration in Schizophrenia

October marks the annual occurrence of several international events aimed at expanding awareness of mental health disorders, including schizophrenia. In this blog post, Spinogenix Chief Science Officer Dr. Peter Vanderklish and Chief Medical Advisor Dr. Craig Erickson provide insights into how synaptic regeneration with SPG302 may provide a new and potentially transformative therapeutic approach in…